C.C.J. (Claire) Dekkers, MSc

No picture available
E-mail:
c.c.j.dekkers umcg.nl

Research

Publications
  1. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

    DIAMOND investigators, Jul-2020, In : Lancet Diabetes & Endocrinology. 8, 7, p. 582-593 12 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. Extending the use of SGLT2 inhibitors from diabetic to non-diabetic kidney disease

    Dekkers, C., 2020, [Groningen]: University of Groningen. 176 p.

    Research output: ThesisThesis fully internal (DIV)

  3. UHPLC-MS/MS method for iohexol determination in human EDTA and lithium-heparin plasma, human urine and in goat- and pig EDTA plasma

    Stevens, J., Wessels, M. A., Roggeveld, J., Koster, R. A., Dekkers, C. C., van Gelder, M. K., Gansevoort, R. T., Heerspink, H. J. & Touw, D. J., 22-Jul-2020, In : Bioanalysis. 12, 14, p. 981-990 10 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?

    Dekkers, C. C. J. & Gansevoort, R. T., 31-Jan-2020, In : Nephrology Dialysis Transplantation. 35, p. 33-42 10 p.

    Research output: Contribution to journalReview articleAcademicpeer-review

  5. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes

    Dekkers, C. C. J., Sjostrom, C. D., Greasley, P. J., Cain, V., Boulton, D. W. & Heerspink, H. J. L., 13-Sep-2019, In : Diabetes obesity & metabolism. 21, 12, p. 2667-2673 7 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (10) »

ID: 40964262